Leerink Swann Downgrades MAP Pharmaceuticals (MAPP) to Market Perform
Tweet
Share
E-mailGet Alerts MAPP Hot Sheet
Price: $28.16 +0.64%
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Leerink Swann downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Outperform to Market Perform with a price target of $25.00 (from $19.00) following yesterday's takeover deal.
"We believe MAPP's $25/share takeout valuation is fair and includes some of the technology value in MAPP's Tempo inhaler device which could be unlocked by development into additional indications and pipeline products down the road."
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.
Shares of MAP Pharmaceuticals closed at $24.71 yesterday.
"We believe MAPP's $25/share takeout valuation is fair and includes some of the technology value in MAPP's Tempo inhaler device which could be unlocked by development into additional indications and pipeline products down the road."
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.
Shares of MAP Pharmaceuticals closed at $24.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades oOh!media (OML:AU) to Equalweight
- Goldman Sachs Downgrades Hysan Development Company Limited (14:HK) (HYSNY) to Sell
- UBS Downgrades Alkane Resources (ALK:AU) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
